TMSP(SH:600671)2025-01-24 09:30Financial Performance - The company expects a net profit attributable to shareholders of between 13 million and 16 million yuan for the year 2024, marking a turnaround from a loss in the previous year[3]. - The net profit for the same period last year was a loss of 38.27 million yuan, indicating a significant improvement in performance[6]. - The company anticipates a net profit of 7 million to 10 million yuan after deducting non-recurring gains and losses for 2024[5]. Factors Contributing to Growth - The increase in profit is attributed to enhanced marketing strategies, product repositioning, and increased sales of health products like Tiepi Fengdou[8]. - The company is actively expanding into new products and fields, including health services and medical devices, contributing to its growth[8]. - Sales and revenue from traditional Chinese medicine products, such as Liuwei Dihuang Oral Liquid, have also increased, positively impacting overall performance[8]. Caution and Future Reporting - The profit forecast is based on preliminary calculations and has not been audited by registered accountants, highlighting the need for caution among investors[9][11]. - The company emphasizes that the financial data will be finalized in the audited annual report for 2024, which will provide more accurate figures[11]. - The company has not identified any significant uncertainties that could affect the accuracy of the profit forecast as of the announcement date[10].